CRIS Current Research Information System

MUSOLINO, ANTONINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.886
NA - Nord America 2.314
EU - Europa 1.402
SA - Sud America 553
AF - Africa 90
OC - Oceania 8
Totale 10.253
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.218
VN - Vietnam 2.082
SG - Singapore 1.312
CN - Cina 1.280
BR - Brasile 443
HK - Hong Kong 431
IT - Italia 399
KR - Corea 271
GB - Regno Unito 256
IN - India 156
FR - Francia 153
DE - Germania 137
JP - Giappone 115
FI - Finlandia 97
RU - Federazione Russa 74
NL - Olanda 56
MX - Messico 47
BD - Bangladesh 44
SE - Svezia 43
AR - Argentina 39
ZA - Sudafrica 32
IE - Irlanda 31
AT - Austria 28
PH - Filippine 28
CA - Canada 27
UA - Ucraina 23
EE - Estonia 22
TH - Thailandia 22
TR - Turchia 20
EC - Ecuador 18
IQ - Iraq 18
ES - Italia 17
ID - Indonesia 16
CH - Svizzera 14
PK - Pakistan 14
PY - Paraguay 13
TW - Taiwan 13
SA - Arabia Saudita 12
CI - Costa d'Avorio 10
CO - Colombia 10
CL - Cile 9
PL - Polonia 9
TG - Togo 9
UZ - Uzbekistan 9
VE - Venezuela 9
AU - Australia 8
JO - Giordania 7
SC - Seychelles 7
BO - Bolivia 6
JM - Giamaica 6
LT - Lituania 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
NP - Nepal 5
PT - Portogallo 5
UY - Uruguay 5
BG - Bulgaria 4
CZ - Repubblica Ceca 4
EG - Egitto 4
ET - Etiopia 4
MA - Marocco 4
MY - Malesia 4
RO - Romania 4
BE - Belgio 3
DZ - Algeria 3
GR - Grecia 3
KE - Kenya 3
KZ - Kazakistan 3
LB - Libano 3
OM - Oman 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
IR - Iran 2
MN - Mongolia 2
MW - Malawi 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AG - Antigua e Barbuda 1
AM - Armenia 1
AZ - Azerbaigian 1
BW - Botswana 1
BZ - Belize 1
CU - Cuba 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
Totale 10.242
Salva come PNG Salva come JPEG
Città #
Singapore 812
Hefei 633
Ho Chi Minh City 585
Hanoi 483
Hong Kong 408
Seoul 262
San Jose 239
Ashburn 212
Southend 211
Santa Clara 178
Fairfield 143
Tokyo 100
Lauterbourg 90
Beijing 85
Boardman 81
Houston 79
New York 75
Helsinki 73
Bologna 71
Los Angeles 70
Seattle 70
Woodbridge 68
Wilmington 67
Da Nang 64
Chandler 61
Council Bluffs 61
Bengaluru 60
Haiphong 58
Cambridge 56
Dallas 56
Dong Ket 54
Princeton 47
Ha Long 45
Buffalo 40
São Paulo 39
Biên Hòa 33
Can Tho 32
Dublin 31
Mexico City 29
Ninh Bình 29
Ann Arbor 28
Hải Dương 27
Chicago 26
Quận Bình Thạnh 26
Vũng Tàu 25
Milan 24
Redondo Beach 24
Thái Nguyên 24
Westminster 23
Lappeenranta 22
Nuremberg 22
Frankfurt am Main 21
Rome 21
Padova 20
The Dalles 20
Nanjing 19
Quận Phú Nhuận 19
Amsterdam 18
Tongling 18
Vienna 18
Medford 17
Điện Bàn 17
Changsha 15
Shanghai 15
Vinh 15
Bắc Ninh 14
San Diego 14
Shenyang 14
Zhengzhou 14
Bắc Giang 13
Guangzhou 13
Quận Bảy 13
Quận Sáu 12
Bangkok 11
Hyderabad 11
Phủ Lý 11
Abidjan 10
Falkenstein 10
Nam Định 10
Phoenix 10
Thái Bình 10
Baghdad 9
Bern 9
Guayaquil 9
Huế 9
Lomé 9
Quảng Ninh 9
San Francisco 9
Thu Dau Mot 9
Thành Phố Bà Rịa 9
Toronto 9
Belo Horizonte 8
Berlin 8
Hebei 8
Jinan 8
Lấp Vò 8
Madrid 8
Quezon City 8
Rio de Janeiro 8
Warsaw 8
Totale 6.766
Salva come PNG Salva come JPEG
Nome #
A narrative review of the principal glucocorticoids employed in cancer 898
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 349
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer 346
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma 177
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 174
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 155
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 149
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030 143
Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study 140
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 138
The descriptive epidemiology of melanoma in Italy has changed - for the better 136
ACTIVITY AND SAFETY OF DOSE-ADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DA-POCH-R) IN VERY ELDERLY PATIENTS WITH POOR-PROGNOSTIC UNTREATED DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA 136
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 132
Lomustine (Chloroethyinitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 130
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 128
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 126
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 125
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 125
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial 124
Influence of Sex and Age on Site of Onset, Morphology, and Site of Metastasis in Colorectal Cancer: A Population-Based Study on Data from Four Italian Cancer Registries 123
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer 118
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 113
Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial 112
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 112
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer - The role of anthrocycline dose intensity 112
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 110
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 109
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 109
Hypertriglyceridaemia with bexarotene in cutaneos T cell Lymphoma: the role of Omega-3 fatty acids 109
Breast Cancer in Italy: Stage and Region Distribution 108
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 107
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 105
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 103
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 101
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 100
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 99
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 98
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer 98
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer 98
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations 96
Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol 96
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 95
P73 and p53 pathway in human breast cancer 94
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 93
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 93
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 93
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 91
The Innate Immune Microenvironment in Metastatic Breast Cancer 90
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 90
HER2 STATUS AS PREDICTOR OF MAMMOGRAPHIC SCREENING DETECTION: COMPARISON OF INTERVAL- AND SCREEN-DETECTED BREAST CANCERS 90
Role of Fcγ receptors in HER2-targeted breast cancer therapy 89
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 89
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy 89
Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003-2017 87
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)] 86
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 85
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 85
MULTIPLE COLORECTAL-ENDOMETRIAL (CEC) AND YOUNG AGE ONSET ENDOMETRIAL CANCER (EC): ARE THEY A FAMILY MARKER FOR HEREDITARY NON-POLYPOSIS COLORECTAL CARCINOMA SYNDROME (HNPCC)? 84
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 83
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 83
Immunoglobulin g fragment c receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with Cetuximab-based therapy 83
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 81
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 79
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study 78
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 76
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 73
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives 70
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 68
Indicators of cure for women living after uterine and ovarian cancers: a population-based study 64
North-south differences in incidence and surveillance of cutaneous malignant melanoma in Italy 62
Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors 61
Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study 53
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 52
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 50
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 49
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 49
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 49
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 47
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 46
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 44
Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy 43
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 41
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial 41
NEW PERSPECTIVES OF SELECTION TESTS FOR THE TREATMENT WITH PARP INHIBITORS OF OVARIAN CANCER PATIENTS: A MINI-REVIEW 40
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 40
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 40
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications 39
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer 37
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 37
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 37
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 36
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 36
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 35
https://researchopenworld.com/at-doctor-level/# 34
Early detection of recurrences in the followup of primary breast cancer in an asymptomatic or symptomatic phase 34
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 32
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 32
Prevalence and indicators of cure of Italian women with vulvar squamous cell carcinoma: A population-based study 32
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 31
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 31
Totale 9.818
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.140
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.140
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202196 0 0 0 0 0 0 0 0 0 0 7 89
2021/2022347 48 24 23 11 50 11 10 39 11 8 45 67
2022/2023273 24 32 15 41 33 26 8 9 53 2 11 19
2023/202468 7 18 3 13 5 4 2 1 4 3 5 3
2024/20251.892 8 79 60 71 203 215 174 104 99 121 221 537
2025/20266.955 1.716 847 709 592 350 228 534 247 933 515 284 0
Totale 10.545